Long-term safety data for semaglutide comes from diabetes trials lasting approximately 2 years and the SELECT cardiovascular outcomes trial with median follow-up of about 3.3 years
Your Health Goals, Delivered
Rita Kapoor help patients understand what to expect from semaglutide GLP-1 therapy and guides them through a personalized weight management plan
To help with that clarity, MeAgain's GLP-1 app offers clear explanations, easy tracking, and personalized insights so you can watch how semaglutide, food, and activity affect insulin sensitivity, mood, and overall hormone balance
FY2026 Update: A new code, E11.A (Type 2 diabetes mellitus in remission), was introduced effective October 1, 2025